Elliot Israel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elliot Israel has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
Juan Carlos Cardet
6 shared publicationsBrianna Ericson
4 shared publicationsMario Castro
Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA
4 shared publicationsMichael E. Wechsler
4 shared publicationsChristopher D. Codispoti
Department of Medicine, Rush University Medical Center, Chicago, Ill; Department of Pediatrics, Stroger Hospital of Cook County, Chicago, Ill
3 shared publicationsDavid J Jackson
Guy's Severe Asthma Centre, School of Immunology & Microbial Sciences, Guy's Hospital, King's College London, London, UK
3 shared publications
Latest Publications
- 3 April 2026
- Published by Elsevier in The Lancet
- Vol. 407 (10536) , 1331
Clinical phenotyping improves choices of biologics in asthma – Authors’ reply
- 3 April 2026
- Published by Elsevier in The Lancet
- Vol. 407 (10536) , 1331
Clinical phenotyping improves choices of biologics in asthma – Authors’ reply
- Top Cited Papers
- 30 September 2025
- Published by Elsevier in The Lancet
- Vol. 406 (10516) , 2282-2294
Anti-cytokine biologics for asthma in adults
- 30 September 2025
- Published by Elsevier in The Lancet
- Vol. 406 (10516) , 2282-2294
Top Cited PapersAnti-cytokine biologics for asthma in adults
- Open Access
- 11 April 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (7) , 1559-1568
Asthma in the Biologics Era: Should Oral Corticosteroid Therapy Be Relegated to History?
- 11 April 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (7) , 1559-1568
Open AccessAsthma in the Biologics Era: Should Oral Corticosteroid Therapy Be Relegated to History?
- Open Access
Electronic health record data analysis on the impact of rescue-triggered inhaled corticosteroids on controller therapy in Black and Latinx individuals from a pragmatic, open-label, patient-level randomised trial
Objective The Person Empowered Asthma Relief (PREPARE) study found that as-needed inhaled corticosteroid (ICS) supplementation combined with participants’ usual controller and rescue therapy reduced asthma exacerbations for Black and Hispanic/Latinx individuals. We aimed to determine whether treatment assignment to the intervention group (Patient Activated Reliever-Triggered ICS (PARTICS)) versus the control group (usual care) influenced controller therapy based on clinicians’ written prescriptions. Design Secondary data analysis of electronic health record data of a pragmatic, open-label, patient-level randomised trial. Setting Practices treating asthma. Participants PREPARE study participants— Black and Hispanic/Latinx individuals with asthma. Interventions Effects of adding ICS to rescue therapy among black and Hispanic adults with moderate-to-severe asthma. Outcome measures For PARTICS therapy impact on patients, each month is the 28-month period (12 months prior to enrolment, the month of enrolment and 15 months after enrolment), a patient was assigned to a controller step based on a six-step classification scheme. A linear mixed effect spline model was completed for before and after enrolment data to determine controller changes over a 28-month period between the two study arms. Results This analysis included 713 participants. Of these, 49.1% were usual care patients and 50.9% were PARTICS patients. Throughout the study, the majority of patients changed asthma controller medications in both arms. By the end of the study, the usual care patients were at a significantly higher asthma controller medication step (0.20 step higher) than the PARTICS patients. Conclusions Clinicians’ prescribing patterns showed significant changes over time. Compared with usual care patients, PARTICS patients were on lower doses of asthma controller medications by the end of the study. Trial registration number NCT02995733.
Open AccessElectronic health record data analysis on the impact of rescue-triggered inhaled corticosteroids on controller therapy in Black and Latinx individuals from a pragmatic, open-label, patient-level randomised trial
Objective The Person Empowered Asthma Relief (PREPARE) study found that as-needed inhaled corticosteroid (ICS) supplementation combined with participants’ usual controller and rescue therapy reduced asthma exacerbations for Black and Hispanic/Latinx individuals. We aimed to determine whether treatment assignment to the intervention group (Patient Activated Reliever-Triggered ICS (PARTICS)) versus the control group (usual care) influenced controller therapy based on clinicians’ written prescriptions. Design Secondary data analysis of electronic health record data of a pragmatic, open-label, patient-level randomised trial. Setting Practices treating asthma. Participants PREPARE study participants— Black and Hispanic/Latinx individuals with asthma. Interventions Effects of adding ICS to rescue therapy among black and Hispanic adults with moderate-to-severe asthma. Outcome measures For PARTICS therapy impact on patients, each month is the 28-month period (12 months prior to enrolment, the month of enrolment and 15 months after enrolment), a patient was assigned to a controller step based on a six-step classification scheme. A linear mixed effect spline model was completed for before and after enrolment data to determine controller changes over a 28-month period between the two study arms. Results This analysis included 713 participants. Of these, 49.1% were usual care patients and 50.9% were PARTICS patients. Throughout the study, the majority of patients changed asthma controller medications in both arms. By the end of the study, the usual care patients were at a significantly higher asthma controller medication step (0.20 step higher) than the PARTICS patients. Conclusions Clinicians’ prescribing patterns showed significant changes over time. Compared with usual care patients, PARTICS patients were on lower doses of asthma controller medications by the end of the study. Trial registration number NCT02995733.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA3564
ARRIVAL: a phase 3b study to assess potential for tezepelumab to reduce maintenance inhaled therapy and induce remission in patients with severe asthma
Background: Biologic therapy may allow patients with severe asthma to reduce or stop maintenance inhaled asthma therapies without loss of asthma control. Objective: ARRIVAL will assess the potential for patients receiving tezepelumab to reduce maintenance inhaled asthma therapy while maintaining asthma control and achieve remission. Methods: Approximately 300 patients with severe, uncontrolled asthma will receive tezepelumab 210 mg every 4 weeks for 72 weeks. At week 24, patients with no exacerbations, who achieve asthma control (Asthma Control Questionnaire [ACQ]-5 score <1.5) and/or low biomarkers with an ACQ-5 score ≤2, will be randomized 2:1 to either step-down or not step-down maintenance inhaled corticosteroids (ICS) until week 56 (Figure). All patients will maintain their ICS dose for weeks 56–72. Results: The primary endpoint is the proportion of patients randomized to step-down ICS who reduce their ICS dose while maintaining asthma control at week 56. Secondary endpoints include the proportions of patients who achieve asthma control and clinical remission at weeks 52 and 72 among those who demonstrated asthma control and characteristics of clinical remission at week 24. Conclusion: ARRIVAL will assess the potential of tezepelumab to enable withdrawal of maintenance ICS while maintaining asthma control in patients with severe, uncontrolled asthma. erj;64/suppl_68/PA3564/F1 F1 F1
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA3564
ARRIVAL: a phase 3b study to assess potential for tezepelumab to reduce maintenance inhaled therapy and induce remission in patients with severe asthma
Background: Biologic therapy may allow patients with severe asthma to reduce or stop maintenance inhaled asthma therapies without loss of asthma control. Objective: ARRIVAL will assess the potential for patients receiving tezepelumab to reduce maintenance inhaled asthma therapy while maintaining asthma control and achieve remission. Methods: Approximately 300 patients with severe, uncontrolled asthma will receive tezepelumab 210 mg every 4 weeks for 72 weeks. At week 24, patients with no exacerbations, who achieve asthma control (Asthma Control Questionnaire [ACQ]-5 score <1.5) and/or low biomarkers with an ACQ-5 score ≤2, will be randomized 2:1 to either step-down or not step-down maintenance inhaled corticosteroids (ICS) until week 56 (Figure). All patients will maintain their ICS dose for weeks 56–72. Results: The primary endpoint is the proportion of patients randomized to step-down ICS who reduce their ICS dose while maintaining asthma control at week 56. Secondary endpoints include the proportions of patients who achieve asthma control and clinical remission at weeks 52 and 72 among those who demonstrated asthma control and characteristics of clinical remission at week 24. Conclusion: ARRIVAL will assess the potential of tezepelumab to enable withdrawal of maintenance ICS while maintaining asthma control in patients with severe, uncontrolled asthma. erj;64/suppl_68/PA3564/F1 F1 F1
- Open Access
- 20 June 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (6)
Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction
Background: Persistent airflow obstruction (PAO) in patients with asthma can be difficult to treat. Tezepelumab blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis. This analysis evaluated the efficacy of tezepelumab in patients with severe, uncontrolled asthma and PAO.Methods: PATHWAY (phase 2b) and NAVIGATOR (phase 3) were multicentre, randomised, double-blind, placebo-controlled studies. Thispost hocanalysis included PATHWAY and NAVIGATOR patients who received tezepelumab 210 mg or placebo every 4 weeks for 52 weeks. Change from baseline to week 52 in pre-bronchodilator forced expiratory volume in 1 s (FEV1) and the annualised asthma exacerbation rate (AAER) over 52 weeks were assessed in patients with and without PAO (post-bronchodilator FEV1/forced vital capacity ratio 1from baseline were observed in tezepelumabversusplacebo recipients with PAO (least-squares (LS) mean 0.24versus0.07 L; difference 0.17 L, 95% confidence interval (CI): 0.11–0.23) and without PAO (LS mean 0.20versus0.12 L; difference 0.08 L, 95% CI: 0.01–0.15). Tezepelumab reduced the AAERversusplacebo by 61% (95% CI: 51–69) and 56% (95% CI: 42–67) in patients with and without PAO, respectively. For patients with PAO at baseline, the proportion without PAO at week 52 was higher with tezepelumab (12.1%) than placebo (6.6%) (odds ratio 1.96, 95% CI: 1.30–2.94).Conclusion: Tezepelumab improved lung function and reduced exacerbationsversusplacebo in patients with severe, uncontrolled asthma with and without PAO.
- 20 June 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (6)
Open AccessEfficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction
Background: Persistent airflow obstruction (PAO) in patients with asthma can be difficult to treat. Tezepelumab blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis. This analysis evaluated the efficacy of tezepelumab in patients with severe, uncontrolled asthma and PAO.Methods: PATHWAY (phase 2b) and NAVIGATOR (phase 3) were multicentre, randomised, double-blind, placebo-controlled studies. Thispost hocanalysis included PATHWAY and NAVIGATOR patients who received tezepelumab 210 mg or placebo every 4 weeks for 52 weeks. Change from baseline to week 52 in pre-bronchodilator forced expiratory volume in 1 s (FEV1) and the annualised asthma exacerbation rate (AAER) over 52 weeks were assessed in patients with and without PAO (post-bronchodilator FEV1/forced vital capacity ratio 1from baseline were observed in tezepelumabversusplacebo recipients with PAO (least-squares (LS) mean 0.24versus0.07 L; difference 0.17 L, 95% confidence interval (CI): 0.11–0.23) and without PAO (LS mean 0.20versus0.12 L; difference 0.08 L, 95% CI: 0.01–0.15). Tezepelumab reduced the AAERversusplacebo by 61% (95% CI: 51–69) and 56% (95% CI: 42–67) in patients with and without PAO, respectively. For patients with PAO at baseline, the proportion without PAO at week 52 was higher with tezepelumab (12.1%) than placebo (6.6%) (odds ratio 1.96, 95% CI: 1.30–2.94).Conclusion: Tezepelumab improved lung function and reduced exacerbationsversusplacebo in patients with severe, uncontrolled asthma with and without PAO.
- Open Access
- 19 July 2023
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 36 (4) , 650-661
What Patients Call Their Inhalers Is Associated with “Asthma Attacks”
Background: Clinician-patient miscommunication contributes to worse asthma outcomes. What patients call their asthma inhalers and its relationship with asthma morbidity are unknown. Methods: Inhaler names were ascertained from Black and Latinx adults with moderate-severe asthma and categorized as “standard” if based on brand/generic name or inhaler type (i.e., controller vs. rescue) or “non-standard” for other terms (i.e., color, device type, e.g., “puffer,” or unique names). Clinical characteristics and asthma morbidity measures were evaluated at baseline: self-reported asthma exacerbations one year before enrollment (i.e., systemic corticosteroid bursts, emergency department (ED)/urgent care (UC) visits, or hospitalizations), and asthma control and quality of life. Multivariable regression models tested the relationship between non-standard names and asthma morbidity measures, with adjustments. Results: Forty-four percent (502/1150) of participants used non-standard inhaler names. These participants were more likely to be Black (p=0.006), from the Southeast (p<0.001), and have fewer years with asthma (p=0.012) relative to those who used standard names. Non-standard inhaler names was associated with an incidence rate ratio (IRR) of 1.29 (95% confidence interval [CI], 1.11-1.50, p=0.001; 1.8 vs. 1.5 events) for corticosteroid bursts for asthma, an IRR=1.43 (95% CI, 1.21-1.69, p<0.001; 1.9 vs. 1.4 events) for ED/UC visits for asthma, and an odds ratio=1.57 (95% CI, 1.12-2.18, p=0.008; 0.5 vs. 0.3 events) for asthma hospitalizations after adjustment. Conclusions: Patients who use non-standard names for asthma inhalers experience increased asthma morbidity. Ascertaining what patients call their inhalers may be a quick method to identify those at higher risk of poor outcomes.
- 19 July 2023
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 36 (4) , 650-661
Open AccessWhat Patients Call Their Inhalers Is Associated with “Asthma Attacks”
Background: Clinician-patient miscommunication contributes to worse asthma outcomes. What patients call their asthma inhalers and its relationship with asthma morbidity are unknown. Methods: Inhaler names were ascertained from Black and Latinx adults with moderate-severe asthma and categorized as “standard” if based on brand/generic name or inhaler type (i.e., controller vs. rescue) or “non-standard” for other terms (i.e., color, device type, e.g., “puffer,” or unique names). Clinical characteristics and asthma morbidity measures were evaluated at baseline: self-reported asthma exacerbations one year before enrollment (i.e., systemic corticosteroid bursts, emergency department (ED)/urgent care (UC) visits, or hospitalizations), and asthma control and quality of life. Multivariable regression models tested the relationship between non-standard names and asthma morbidity measures, with adjustments. Results: Forty-four percent (502/1150) of participants used non-standard inhaler names. These participants were more likely to be Black (p=0.006), from the Southeast (p<0.001), and have fewer years with asthma (p=0.012) relative to those who used standard names. Non-standard inhaler names was associated with an incidence rate ratio (IRR) of 1.29 (95% confidence interval [CI], 1.11-1.50, p=0.001; 1.8 vs. 1.5 events) for corticosteroid bursts for asthma, an IRR=1.43 (95% CI, 1.21-1.69, p<0.001; 1.9 vs. 1.4 events) for ED/UC visits for asthma, and an odds ratio=1.57 (95% CI, 1.12-2.18, p=0.008; 0.5 vs. 0.3 events) for asthma hospitalizations after adjustment. Conclusions: Patients who use non-standard names for asthma inhalers experience increased asthma morbidity. Ascertaining what patients call their inhalers may be a quick method to identify those at higher risk of poor outcomes.
- 1 May 2023
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 29 (3) , 209-214
As-needed inhaled corticosteroids as add-on therapy versus SMART therapy: an evolving understanding of the two approaches in the management of moderate-to-severe asthma
Purpose of review: Asthma is the most common chronic respiratory disorder, characterized by recurring, reversible airflow obstruction due to inflammation and airway hyperresponsiveness. Although biologics have provided significant advances in the treatment of asthma, they are expensive, and their use remains restricted to more severe asthma. Additional approaches in the management of moderate-to-severe asthma are necessary. Recent findings: ICS–formoterol as maintenance and reliever therapy in asthma and its effect on improved asthma control has been demonstrated in multiple cohorts of asthma. Although ICS–formoterol as maintenance and reliever therapy has been widely validated, there are significant design considerations including the requirement for exacerbation and bronchodilator response and the lack of evidence for effectiveness in patients who use nebulized reliever therapies, which may limit the use of this therapy in selected populations. More recent trials of as-needed ICS have demonstrated effectiveness in reducing asthma exacerbations and improvements in asthma control and may provide an additional therapeutic strategy for individuals with moderate-to-severe asthma. Summary: Both ICS–formoterol as a maintenance and a reliever as well as as-needed ICS have demonstrated significant improvements in the control of moderate-to-severe asthma. Future investigational work will be necessary to elucidate whether a strategy of ICS–formoterol as maintenance and reliever therapy or an as-needed ICS strategy demonstrates superiority in asthma control in the context of the cost to individual patients and health systems.
- 1 May 2023
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 29 (3) , 209-214
As-needed inhaled corticosteroids as add-on therapy versus SMART therapy: an evolving understanding of the two approaches in the management of moderate-to-severe asthma
Purpose of review: Asthma is the most common chronic respiratory disorder, characterized by recurring, reversible airflow obstruction due to inflammation and airway hyperresponsiveness. Although biologics have provided significant advances in the treatment of asthma, they are expensive, and their use remains restricted to more severe asthma. Additional approaches in the management of moderate-to-severe asthma are necessary. Recent findings: ICS–formoterol as maintenance and reliever therapy in asthma and its effect on improved asthma control has been demonstrated in multiple cohorts of asthma. Although ICS–formoterol as maintenance and reliever therapy has been widely validated, there are significant design considerations including the requirement for exacerbation and bronchodilator response and the lack of evidence for effectiveness in patients who use nebulized reliever therapies, which may limit the use of this therapy in selected populations. More recent trials of as-needed ICS have demonstrated effectiveness in reducing asthma exacerbations and improvements in asthma control and may provide an additional therapeutic strategy for individuals with moderate-to-severe asthma. Summary: Both ICS–formoterol as a maintenance and a reliever as well as as-needed ICS have demonstrated significant improvements in the control of moderate-to-severe asthma. Future investigational work will be necessary to elucidate whether a strategy of ICS–formoterol as maintenance and reliever therapy or an as-needed ICS strategy demonstrates superiority in asthma control in the context of the cost to individual patients and health systems.
- 29 June 2022
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 150 (5) , 1106-1113.e10
Caribbean Latinx with moderate-severe asthma bear greater asthma morbidity than other Latinx
- 29 June 2022
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 150 (5) , 1106-1113.e10
Caribbean Latinx with moderate-severe asthma bear greater asthma morbidity than other Latinx
- 18 May 2022
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 150 (4) , 841-849.e4
Socioeconomic status associates with worse asthma morbidity among Black and Latinx adults
- 18 May 2022
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 150 (4) , 841-849.e4
Socioeconomic status associates with worse asthma morbidity among Black and Latinx adults